Key Takeaways OPRX posted 11% revenue growth and $1.5M adjusted EBITDA, its best Q1 showing to date. 80% of OPRX's FY25 revenue guidance is covered by contracts; subscription share exceeds 5%. OPRX's Gross margin dipped to 60.9% as a lower-margin DTC mix weighed on profitability.OptimizeRx (OPRX) kicked off 2025 with strong momentum, delivering 11% year-over-year revenue growth to $21.9 million and turning in $1.5 million in adjusted EBITDA, its strongest first-quarter performance to date. The digital hea ...

公司合作动态 - Veeva Systems宣布Astellas选择其Veeva Vault CRM全球解决方案及Veeva China CRM中国解决方案 [1] - Astellas首席数字与转型官Nick Eshkenazi表示，与Veeva合作将提供技术解决方案和数据，增强公司商业敏捷性和执行力 [2] - Veeva商业战略总裁Matt Farrell称，Vault CRM将深化与Astellas的合作伙伴关系，支持其通过创新科学改善全球健康的使命 [2] 产品与技术 - Vault CRM满足行业独特的、不断变化的国别业务需求和合规要求 [2] - Vault CRM Suite连接销售、营销和医疗团队，实现无缝协作和更有效的商业执行 [2] 公司背景 - Veeva Systems是生命科学行业云软件的全球领导者，服务超过1,000家客户，包括大型生物制药公司和新兴生物技术企业 [3] - 作为一家公益公司，Veeva致力于平衡客户、员工、股东及所服务行业的利益 [3]